{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:21:44Z","timestamp":1784409704287,"version":"3.55.0"},"reference-count":26,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v103.9646","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T11:46:55Z","timestamp":1690890415000},"page":"adv9646","source":"Crossref","is-referenced-by-count":9,"title":["Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report"],"prefix":"10.2340","volume":"103","author":[{"given":"Han Seul","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Joon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"35635","doi-asserted-by":"crossref","unstructured":"Crowson AN, Mihm MC, Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003; 30: 97-107.","DOI":"10.1034\/j.1600-0560.2003.00024.x"},{"key":"35636","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1034\/j.1600-0560.2003.00024.x","DOI":"10.1034\/j.1600-0560.2003.00024.x"},{"key":"35637","doi-asserted-by":"crossref","unstructured":"Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 2018; 14: 225-233.","DOI":"10.1080\/1744666X.2018.1438269"},{"key":"35638","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/1744666X.2018.1438269","DOI":"10.1080\/1744666X.2018.1438269"},{"key":"35639","doi-asserted-by":"crossref","unstructured":"Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol 2017; 177: 72-83.","DOI":"10.1111\/bjd.15193"},{"key":"35640","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.15193","DOI":"10.1111\/bjd.15193"},{"key":"35641","doi-asserted-by":"crossref","unstructured":"Tsibris H, Lian C, Ho A. Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma. Dermatol Online J 2021; 27.","DOI":"10.5070\/D3274053158"},{"key":"35642","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5070\/D3274053158","DOI":"10.5070\/D3274053158"},{"key":"35643","doi-asserted-by":"crossref","unstructured":"Rudolph BM, Staib F, Von Stebut E, Hainz M, Grabbe S, Loquai C. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma - simultaneous occurrence of pyoderma gangrenosum and colitis. Eur J Dermatol 2014; 24: 268-269.","DOI":"10.1684\/ejd.2014.2297"},{"key":"35644","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1684\/ejd.2014.2297","DOI":"10.1684\/ejd.2014.2297"},{"key":"35645","doi-asserted-by":"crossref","unstructured":"Welborn ME, Kubicki SL, Patel AB. Pyoderma gangrenosum following initiation of immune checkpoint inhibitor therapy. J Immunother Precis Oncol 2018; 1: 82-84.","DOI":"10.4103\/JIPO.JIPO_11_18"},{"key":"35646","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/JIPO.JIPO_11_18","DOI":"10.4103\/JIPO.JIPO_11_18"},{"key":"35647","doi-asserted-by":"crossref","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382: 1894-1905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"35648","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1915745","DOI":"10.1056\/NEJMoa1915745"},{"key":"35649","doi-asserted-by":"crossref","unstructured":"Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol 2020; 83: 1130-1143.","DOI":"10.1016\/j.jaad.2020.04.105"},{"key":"35650","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.105","DOI":"10.1016\/j.jaad.2020.04.105"},{"key":"35651","doi-asserted-by":"crossref","unstructured":"Ellis C, M. M, LaFond A, Fivenson D. An interesting case of pyoderma gangrenosum. J Am Acad Dermatol 2016; 74.","DOI":"10.1016\/j.jaad.2016.02.1127"},{"key":"35652","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1127","DOI":"10.1016\/j.jaad.2016.02.1127"},{"key":"35653","doi-asserted-by":"crossref","unstructured":"Akanay-Diesel S, Hoff NP, Kurle S, Haes J, Erhardt A, Haussinger D, et al. Sunitinib induced pyoderma gangrenosum-like ulcerations. Eur J Med Res 2011; 16: 491-494.","DOI":"10.1186\/2047-783X-16-11-491"},{"key":"35654","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/2047-783X-16-11-491","DOI":"10.1186\/2047-783X-16-11-491"},{"key":"35655","doi-asserted-by":"crossref","unstructured":"Scheinberg M, Machado LA, LG MC, Ferreira SB, Michalany N. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun 2021; 4: 100099.","DOI":"10.1016\/j.jtauto.2021.100099"},{"key":"35656","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jtauto.2021.100099","DOI":"10.1016\/j.jtauto.2021.100099"},{"key":"35657","doi-asserted-by":"crossref","unstructured":"Sitaru S, Biedermann T, Lauffer F. Successful treatment of pyoderma gangrenosum with Janus kinase 1\/2 inhibition. JEADV Clinical Practice 2022; 1: 420-423.","DOI":"10.1002\/jvc2.62"},{"key":"35658","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/jvc2.62","DOI":"10.1002\/jvc2.62"},{"key":"35659","doi-asserted-by":"crossref","unstructured":"Ortega-Loayza AG, Friedman MA, Reese AM, Liu Y, Greiling TM, Cassidy PB, et al. Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression. J Invest Dermatol 2022; 142: 1217-1220.e4.","DOI":"10.1016\/j.jid.2021.08.431"},{"key":"35660","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2021.08.431","DOI":"10.1016\/j.jid.2021.08.431"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/9646\/22173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/9646\/22173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T11:47:04Z","timestamp":1690890424000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/9646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":26,"URL":"https:\/\/doi.org\/10.2340\/actadv.v103.9646","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}